Barecetamab

巴瑞赛妥单抗

Report date: 2024/11/19 20:00:10

Base Information

Drug NameBarecetamab
Drug Alias NameISU-104
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 modulators
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIsu Abxis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIsu Abxis Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A